ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncogene
Main Authors: Berns, Katrien, Caumanns, Joseph J., Hijmans, E. Marielle, Gennissen, Annemiek M. C., Severson, Tesa M., Evers, Bastiaan, Wisman, G. Bea A., Jan Meersma, Gert, Lieftink, Cor, Beijersbergen, Roderick L., Itamochi, Hiroaki, van der Zee, Ate G. J., de Jong, Steven, Bernards, René
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095834/
https://ncbi.nlm.nih.gov/pubmed/29760405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0300-6
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki